| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 01/09/2014 | US20140011876 Composition and method for treatment of diabetes |
| 01/09/2014 | US20140011869 Compositions and methods of treatment with proanthocyanidin polymer antidiarrheal compositions |
| 01/09/2014 | US20140011854 ST-246 Liquid Formulations and Methods |
| 01/09/2014 | US20140011842 Oral Pharmaceutical Dosage Forms |
| 01/09/2014 | US20140011832 Encased Tamper Resistant Controlled Release Dosage Forms |
| 01/09/2014 | US20140011788 Pharmaceutical composition and method for treating hypogonadism |
| 01/09/2014 | US20140011780 Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols |
| 01/09/2014 | US20140011753 Cyclosporin compositions |
| 01/09/2014 | US20140010894 Sustained release beads and suspensions including the same for sustained delivery of active ingredients |
| 01/09/2014 | US20140010885 Self-assembling nanoparticle drug delivery system |
| 01/09/2014 | US20140010883 Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor |
| 01/09/2014 | US20140010882 Pharmaceutical composition for treating a disease in the oral cavity comprising rebamipide |
| 01/09/2014 | US20140010880 Tricalcium Phosphate Coarse Particle Compositions and Methods for Making the Same |
| 01/09/2014 | US20140010879 Compositions and methods of treating therapy resistant cancer and uses thereof |
| 01/09/2014 | US20140010878 Pharmaceutical compositions containing flibanserin |
| 01/09/2014 | US20140010876 Pharmaceutical administration forms comprising 5-chloro-n-(methyl)-2-thiophenecarboxamide |
| 01/09/2014 | US20140010875 Encased Tamper Resistant Controlled Release Dosage Forms |
| 01/09/2014 | US20140010874 Tamper Resistant Solid Oral Dosage Forms |
| 01/09/2014 | US20140010873 Abuse deterrent pharmaceutical compositions for controlled release |
| 01/09/2014 | US20140010872 Oral complex composition comprising omega-3 fatty acid ester and hmg-coa reductase inhibitor |
| 01/09/2014 | US20140010870 Pharmaceutical formulation comprising inositol |
| 01/09/2014 | US20140010869 Formulation and manufacturing process for calcium acetate capsules |
| 01/09/2014 | US20140010866 Methods and systems for treatment of migraines and other indications |
| 01/09/2014 | US20140010864 Liposomes for protection against toxic compounds |
| 01/09/2014 | US20140010863 Liposomes for protection against toxic compounds |
| 01/09/2014 | US20140010861 Modified polynucleotides for the production of proteins associated with human disease |
| 01/09/2014 | US20140010860 Abuse and alcohol resistant drug composition |
| 01/09/2014 | US20140010859 Barley protein microcapsules |
| 01/09/2014 | US20140010848 Gas-filled microbubbles and systems for gas delivery |
| 01/09/2014 | US20140010806 Treatment of Ocular Diseases |
| 01/09/2014 | US20140010771 Allantoin-Containing Skin Cream |
| 01/09/2014 | US20140010765 Micronutrient supplement dispensing package |
| 01/09/2014 | US20140010760 Hypoxia-Targeted Polymeric Micelles For Cancer Therapy And Imaging |
| 01/09/2014 | US20140008830 Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
| 01/09/2014 | US20140008264 Biodegradable Natural Films Based on Co-Products Derived from Industrial-Scale Seed-Treatment Processes |
| 01/09/2014 | US20140007873 Dry powder inhaler and system for drug delivery |
| 01/09/2014 | CA2878376A1 Transdermally absorbable preparation containing rotigotine |
| 01/09/2014 | CA2878152A1 Methods of treating arthritis |
| 01/09/2014 | CA2878128A1 Hydrogel vaccine formulations |
| 01/09/2014 | CA2878123A1 Pharmaceutical administration forms comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide |
| 01/09/2014 | CA2878102A1 A topical composition comprising a film-forming polymer for delivering an active ingredient to skin |
| 01/09/2014 | CA2878026A1 Microparticles for encapsulating probiotics, obtaining said microparticles and uses thereof |
| 01/09/2014 | CA2877805A1 Use of an inhibitor of irs-1 for treating skin disorders |
| 01/09/2014 | CA2877183A1 Abuse deterrent pharmaceutical compositions for controlled release |
| 01/09/2014 | CA2876883A1 Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
| 01/09/2014 | CA2874815A1 Pharmaceutical compositions comprising rifaximin and amino acids, preparation method and use thereof |
| 01/08/2014 | EP2682467A1 Use of an inhibitor of IRS-1 for treating skin disorders |
| 01/08/2014 | EP2682130A1 Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound |
| 01/08/2014 | EP2682129A2 Compositions Comprising Muscarinic Receptor Antagonist and Glucose Anhydrous |
| 01/08/2014 | EP2682113A1 Sealing laminates containing agents |
| 01/08/2014 | EP2682112A1 Combined capsule formulations of flurbiprofen and famotidine |
| 01/08/2014 | EP2682111A1 Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols |
| 01/08/2014 | EP2682110A1 Laminated tablet and manufacturing method therefor |
| 01/08/2014 | EP2682109A1 Combined immediate release formulations of flurbiprofen and famotidine |
| 01/08/2014 | EP2682108A2 Dry Powder Inhalers Comprising a Carrier Other Than Lactose and a Ternary Component |
| 01/08/2014 | EP2682107A1 Palatable electrolyte-based composition for oral rehydration |
| 01/08/2014 | EP2682106A1 Method of solubilizing biologically active compounds |
| 01/08/2014 | EP2682105A1 Orally-disintegrating formulations of dexketoprofen |
| 01/08/2014 | EP2682104A1 Orally-disintegrating formulations of dexketoprofen |
| 01/08/2014 | EP2682103A2 Compositions Comprising Muscarinic Receptor Antagonist and Sorbitol |
| 01/08/2014 | EP2682102A2 Inhalation Compositions Comprising Corticosteroid and Sorbitol |
| 01/08/2014 | EP2682101A2 Inhalation Compositions Comprising Glucose Anhydrous |
| 01/08/2014 | EP2682100A2 Inhalation Compositions Comprising Muscarinic Receptor Antagonist |
| 01/08/2014 | EP2682099A1 Dry Powder Inhaler Compositions Comprising Long Acting Muscorinic Antagonists |
| 01/08/2014 | EP2682098A2 Inhalation Compositions |
| 01/08/2014 | EP2682097A2 Dry Powder Inhalers Comprising A Carrier Other Than Lactose |
| 01/08/2014 | EP2682094A1 Manufacturing method for o/w emulsion composition |
| 01/08/2014 | EP2681264A1 Producing powdery coating agents for stable protective coatings for pharmaceutical dosage forms |
| 01/08/2014 | EP2681263A1 Producing powdery coating agents for stable protective coatings for pharmaceutical dosage forms |
| 01/08/2014 | EP2680919A2 Immunologically modified carbon nanotubes for cancer treatment |
| 01/08/2014 | EP2680918A2 Transdermal patch containing microneedles |
| 01/08/2014 | EP2680881A1 Vaccination in elderly patients |
| 01/08/2014 | EP2680880A1 Vaccination in newborns and infants |
| 01/08/2014 | EP2680869A2 Homeopathic therapeutic method and compositions |
| 01/08/2014 | EP2680862A1 Encapsulated cells for hormone replacement therapy |
| 01/08/2014 | EP2680848A1 Stable compositions of tetrahydrobiopterin |
| 01/08/2014 | EP2680846A1 Use of n-(4-methoxyphenyl)-1-phenyl-1h-pyrazol-3-amine and related compounds |
| 01/08/2014 | EP2680841A1 Use of glycopyrrolate for treating tachycardia |
| 01/08/2014 | EP2680834A1 Semisolid aqueous pharmaceutical composition containing tapentadol |
| 01/08/2014 | EP2680833A1 Parenteral administration of tapentadol |
| 01/08/2014 | EP2680832A1 Aqueous pharmaceutical formulation of tapentadol for oral administration |
| 01/08/2014 | EP2680828A1 Chewable vehicle for mouth absorption |
| 01/08/2014 | EP2680827A1 Particles containing a growth factor, and uses thereof |
| 01/08/2014 | EP2680826A1 Vitamin d composition |
| 01/08/2014 | EP2680825A1 Prucalopride oral solution |
| 01/08/2014 | EP2680824A1 Coated solid pharmaceutical preparation |
| 01/08/2014 | EP2680823A1 Binder powders |
| 01/08/2014 | EP2680822A1 Vesicle compositions |
| 01/08/2014 | EP2680821A2 Liposome formulation comprising an anti-tumour active substance, method for its preparation and pharmaceutical compositions comprising it |
| 01/08/2014 | EP2680820A1 Advanced active liposomal loading of poorly water-soluble substances |
| 01/08/2014 | EP2680818A1 Chemical composition with hydrogen peroxide and a nanoemulsion of long-chained alcohols |
| 01/08/2014 | EP2680817A2 Use of a viscoelastic fluid for producing a medicinal product for surgically treating the eye |
| 01/08/2014 | EP2680816A1 Non-aqueous silicone-based ophthalmic formulations |
| 01/08/2014 | EP2680815A1 Porous disintegratable solid substrate for personal health care applications |
| 01/08/2014 | EP2680814A2 Silicone-based ophthalmic formulations |
| 01/08/2014 | EP2680813A1 Diethylstilbestrol dosage form and use for the treatment of prostate or breast cancer |
| 01/08/2014 | CN103502319A Pharmaceutical composition containing block copolymer comprising boric acid compound |
| 01/08/2014 | CN103502214A Prodrugs of D-isoglutamyl-[D/L]-tryptophan |
| 01/08/2014 | CN103501820A Tolerogenic synthetic nanocarriers for antigen-specific deletion of T effector cells |
| 01/08/2014 | CN103501813A Tolerogenic synthetic nanocarriers to reduce antibody responses |